Aktienanalyse zu NeOnc Technologies Holdings Inc (NTHI)NTHINeOnc Technologies Holdings Inc

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. It is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. It is developing novel drug delivery methods to be used in combination with novel drug candidates. The Company has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others). It operates in the Healthcare sector.

Neonc Technologies Holdings, Inc. appears to be a good buy right now due to its recent positive clinical trial results, showing a 48.9% six-month progression-free survival rate, which significantly exceeds the pre-specified 20% benchmark. The current price is $4.69, and with analyst price targets reaching as high as $20, this presents a potential upside of over 325%. Additionally, the RSI is at 57.858, indicating that the stock is in a healthy momentum range. However, the main risk is the company's ongoing negative earnings, with a reported EPS of -0.58, which highlights the need for continued monitoring of financial performance.